Clinical Trial: A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
Study Status: Completed
Recruit Status: Completed
Condition: Retinopathy of Prematurity
Study Type: Interventional
Official Title: A Dosing Study of Two Different Doses (0.3125mg Versus 0.625mg) Intravitreal Bevacizumab for Type 1 ROP (Retinopathy of Prematurity)
Brief Summary:
The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :Serum Systemic VEGF levels. Retinal Vascularization.
Read more